The COOH-terminal domain of wild-type cot regulates its stability and kinase specific activity

被引:46
作者
Gándara, ML [1 ]
López, P [1 ]
Hernando, R [1 ]
Castaño, JG [1 ]
Alemany, S [1 ]
机构
[1] UAM, CSIC, Inst Invest Biomed Alberto Sols, Consejo Super Invest Cient,Fac Med, Madrid 28029, Spain
关键词
D O I
10.1128/MCB.23.20.7377-7390.2003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cot, initially identified as an oncogene in a truncated form, is a mitogen-activated protein kinase kinase kinase implicated in cellular activation and proliferation. Here, we show that this truncation of Cot results in a 10-fold increase in its overall kinase activity through two different mechanisms. Truncated Cot protein exhibits a lower turnover rate (half-life, 95 min) than wild-type Cot (half-life, 35 min). The degradation of wild-type and truncated Cot can be specifically inhibited by proteasome inhibitors in situ. The 20S proteasome also degrades wild-type Cot more efficiently than the truncated protein. Furthermore, the amino acid 435 to 457 region within the wild-type Cot COOH-terminal domain confers instability when transferred to the yellow fluorescent protein and targets this fusion protein to degradation via the proteasome. On the other hand, the kinase specific activity of wild-type Cot is 3.8-fold lower than that of truncated Cot, and it appears that the last 43 amino acids of the wild-type Cot COOH-terminal domain are those responsible for this inhibition of kinase activity. In conclusion, these data demonstrate that the oncogenic activity of truncated Cot is the result of its prolonged half-life and its higher kinase specific activity with respect to wild-type Cot.
引用
收藏
页码:7377 / 7390
页数:14
相关论文
共 71 条
[51]  
PATSCHINSKY T, 1988, ONCOGENE, V3, P357
[52]  
PEREIRA ME, 1992, J BIOL CHEM, V267, P7949
[53]   MOS STIMULATES MAP KINASE IN XENOPUS OOCYTES AND ACTIVATES A MAP KINASE KINASE INVITRO [J].
POSADA, J ;
YEW, N ;
AHN, NG ;
VANDEWOUDE, GF ;
COOPER, JA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (04) :2546-2553
[54]  
Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1
[55]   Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase [J].
Salmeron, A ;
Ahmad, TB ;
Carlile, GW ;
Pappin, D ;
Narsimhan, RP ;
Ley, SC .
EMBO JOURNAL, 1996, 15 (04) :817-826
[56]   COT kinase proto-oncogene expression in T cells -: Implication of the JNK/SAPK signal transduction pathway in COT promoter activation [J].
Sánchez-Góngora, E ;
Lisbona, C ;
de Gregorio, R ;
Ballester, A ;
Calvo, V ;
Pérez-Jurado, L ;
Alemany, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (40) :31379-31386
[57]   JUN-B INHIBITS AND C-FOS STIMULATES THE TRANSFORMING AND TRANS-ACTIVATING ACTIVITIES OF C-JUN [J].
SCHUTTE, J ;
VIALLET, J ;
NAU, M ;
SEGAL, S ;
FEDORKO, J ;
MINNA, J .
CELL, 1989, 59 (06) :987-997
[58]   Dissection of c-MOS degron [J].
Sheng, J ;
Kumagai, A ;
Dunphy, WG ;
Varshavsky, A .
EMBO JOURNAL, 2002, 21 (22) :6061-6071
[59]   MOS INDUCES THE IN-VITRO ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES IN LYSATES OF FROG OOCYTES AND MAMMALIAN SOMATIC-CELLS [J].
SHIBUYA, EK ;
RUDERMAN, JV .
MOLECULAR BIOLOGY OF THE CELL, 1993, 4 (08) :781-790
[60]   Overexpression of the Tpl-2/Cot oncogene in human breast cancer [J].
Sourvinos, G ;
Tsatsanis, C ;
Spandidos, DA .
ONCOGENE, 1999, 18 (35) :4968-4973